Information Provided By: 
Fly News Breaks for May 4, 2018
SRPT
May 4, 2018 | 09:22 EDT
Leerink analyst Joseph Schwartz said Sarepta's "hot streak hit a mostly expected blip" with Exondys51 sales coming in below expectation and EMA news that slows progress in Europe. While he is delaying his EU launch assumptions for eteplirsen, golodirsen, and casimersen due to the latest CHMP development, Schwartz sees the base business and pipeline progress being intact and he maintains an Outperform rating on Sarepta shares, though he lowered his price target to $88 from $92.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
